Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta
- PMID: 32599856
- PMCID: PMC7357118
- DOI: 10.3390/biom10060953
Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta
Abstract
Preeclampsia (PE) is a serious pregnancy complication, affecting about 5-7% of pregnancies worldwide and is characterized by hypertension and damage to multiple maternal organs, primarily the liver and kidneys. PE usually begins after 20 weeks' gestation and, if left untreated, can lead to serious complications and lifelong disabilities-even death-in both the mother and the infant. As delivery is the only cure for the disease, treatment is primarily focused on the management of blood pressure and other clinical symptoms. The pathogenesis of PE is still not clear. Abnormal spiral artery remodeling, placental ischemia and a resulting increase in the circulating levels of vascular endothelial growth factor receptor-1 (VEGFR-1), also called soluble fms-like tyrosine kinase-1 (sFlt-1), are believed to be among the primary pathologies associated with PE. sFlt-1 is produced mainly in the placenta during pregnancy and acts as a decoy receptor, binding to free VEGF (VEGF-A) and placental growth factor (PlGF), resulting in the decreased bioavailability of each to target cells. Despite the pathogenic effects of increased sFlt-1 on the maternal vasculature, recent studies from our laboratory and others have strongly indicated that the increase in sFlt-1 in PE may fulfill critical protective functions in preeclamptic pregnancies. Thus, further studies on the roles of sFlt-1 in normal and preeclamptic pregnancies are warranted for the development of therapeutic strategies targeting VEGF signaling for the treatment of PE. Another impediment to the treatment of PE is the lack of suitable methods for delivery of cargo to placental cells, as PE is believed to be of placental origin and most available therapies for PE adversely impact both the mother and the fetus. The present review discusses the pathogenesis of PE, the complex role of sFlt-1 in maternal disease and fetal protection, and the recently developed placenta-targeted drug delivery system for the potential treatment of PE with candidate therapeutic agents.
Keywords: cytotrophoblasts; pathogenesis; placenta; preeclampsia; spiral artery.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7357118/bin/biomolecules-10-00953-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7357118/bin/biomolecules-10-00953-g002.gif)
Similar articles
-
In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.Am J Obstet Gynecol. 2016 Dec;215(6):782.e1-782.e9. doi: 10.1016/j.ajog.2016.07.056. Epub 2016 Aug 5. Am J Obstet Gynecol. 2016. PMID: 27503620
-
Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.Am J Physiol Heart Circ Physiol. 2018 Jul 1;315(1):H33-H47. doi: 10.1152/ajpheart.00045.2018. Epub 2018 Mar 23. Am J Physiol Heart Circ Physiol. 2018. PMID: 29569955 Free PMC article.
-
Expert review: preeclampsia Type I and Type II.Am J Obstet Gynecol MFM. 2023 Dec;5(12):101203. doi: 10.1016/j.ajogmf.2023.101203. Epub 2023 Oct 21. Am J Obstet Gynecol MFM. 2023. PMID: 37871693 Review.
-
EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion.Hypertension. 2019 Mar;73(3):659-670. doi: 10.1161/HYPERTENSIONAHA.118.12300. Hypertension. 2019. PMID: 30636550
-
Human Placenta and Evolving Insights into Pathological Changes of Preeclampsia: A Comprehensive Review of the Last Decade.Fetal Pediatr Pathol. 2024 Jan-Feb;43(1):33-46. doi: 10.1080/15513815.2023.2274823. Epub 2024 Jan 24. Fetal Pediatr Pathol. 2024. PMID: 37906285 Review.
Cited by
-
Renalase Levels are Decreased in Maternal Blood and Placental Tissues in Pregnancies Associated with Preterm Preeclampsia.Res Sq [Preprint]. 2024 May 6:rs.3.rs-4319658. doi: 10.21203/rs.3.rs-4319658/v1. Res Sq. 2024. PMID: 38765989 Free PMC article. Preprint.
-
Excessive endometrial PlGF- Rac1 signalling underlies endometrial cell stiffness linked to pre-eclampsia.Commun Biol. 2024 May 4;7(1):530. doi: 10.1038/s42003-024-06220-7. Commun Biol. 2024. PMID: 38704457 Free PMC article.
-
The Pathophysiological, Genetic, and Hormonal Changes in Preeclampsia: A Systematic Review of the Molecular Mechanisms.Int J Mol Sci. 2024 Apr 20;25(8):4532. doi: 10.3390/ijms25084532. Int J Mol Sci. 2024. PMID: 38674114 Free PMC article. Review.
-
Detection of Urinary Misfolded Proteins for Imminent Prediction of Preeclampsia in Pregnant Women With Suspected Cases: Protocol for a Prospective Noninterventional Study.JMIR Res Protoc. 2024 Apr 26;13:e54026. doi: 10.2196/54026. JMIR Res Protoc. 2024. PMID: 38669061 Free PMC article.
-
Enhanced Antioxidative Capacity Transfer between Sow and Fetus via the Gut-Placenta Axis with Dietary Selenium Yeast and Glycerol Monolaurate Supplementation during Pregnancy.Antioxidants (Basel). 2024 Jan 23;13(2):141. doi: 10.3390/antiox13020141. Antioxidants (Basel). 2024. PMID: 38397739 Free PMC article.
References
-
- Hogan M., Foreman K., Naghavi M., Ahn S., Wang M., Makela S., Lopez A., Lozano R., Murray C.J. Maternal Mortality for 181 Countries, 1980–2008. Obstet. Anesthesia Dig. 2011;31:69. doi: 10.1097/01.aoa.0000397097.96320.28. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous